NCT03232983View on ClinicalTrials.gov

A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

November 9, 2017

Study Completion Date

November 9, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY900014 (SC)

Administered SC

DRUG

LY900014 (IV)

Administered IV

Trial Locations (1)

117597

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03232983 - A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants | Biotech Hunter | Biotech Hunter